Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Surveyor Capital

Investor type Hedge Fund

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 112
Average round size
info
The average size of a deal this fund participated in
$115M
Portfolio companies 98
Rounds per year 8.00
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Exits 41
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

Surveyor Capital appeared to be the VC, which was created in 2008.

Among the various public portfolio startups of the fund, we may underline Allogene Therapeutics, Annexon Biosciences, Oncorus The fund has exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Health Diagnostics, Pharmaceutical.

The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Surveyor Capital, startups are often financed by Skyline Ventures, SV Health Investors, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Alexandria Venture Investments, Samsara BioCapital. In the next rounds fund is usually obtained by Roche Venture Fund.

The top amount of exits for fund were in 2019. The top activity for fund was in 2019. This Surveyor Capital works on 11 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 50 - 100 millions dollars.

The overall number of key employees were 3.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Surveyor Capital:
Typical Co-investors
Surveyor Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Surveyor Capital:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
20/20 HealthCare Partners Auburndale, Massachusetts, United States
Associated Bank Green Bay, United States, Wisconsin
Blue Horizon Ventures Switzerland, Zürich, Zurich
Changying Technology China, Guangdong Province, Maoming City
Chisage China, Ningbo, Zhejiang
Concept2Company Ventures California, Stanford, United States
DGC China, Guangdong, Shenzhen
Fubon Financial Holdings -
Gameloft Barcelona, Catalonia, Spain
J-Ventures California, Palo Alto, United States
OakStone Ventures California, Palo Alto, United States
PJT Partners New York, New York, United States
Prepaid Technologies Alabama, Birmingham, United States
Sciencons -
Specialized Types California, San Francisco, United States
Stundi Phuket, Phuket Province, Thailand
Symantec Ventures -
Virginia Tech Carilion (VTC) Innovation Fund Roanoke, United States, Virginia
Wattsense Participations -
Youdu Qiye Guanli Zixun China, Tianjin, Wuqing

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

VectivBio

Biotechnology
Health Care
Medical
$125M13 Oct 2022 Basel, Basel-City, Switzerland

Allakos

Biopharma
Biotechnology
Health Care
Therapeutics
$150M19 Sep 2022 California, United States

ACELYRIN

Biopharma
Biotechnology
Health Care
$300M13 Sep 2022 Los Angeles, California, United States

Remix Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$70M17 May 2022 Cambridge, Massachusetts, United States

MoonLake Immunotherapeutics

$115M06 Apr 2022 Zug, Zug, Switzerland

Neuron23

Health Care
Medical
$100M30 Mar 2022 San Francisco, California, United States

Plexium

Biotechnology
Health Care
Medical
Pharmaceutical
Therapeutics
$102M23 Feb 2022 San Diego, California, United States

Arkuda Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$64M10 Feb 2022 Cambridge, Massachusetts, United States

Metagenomi

Artificial Intelligence
Machine Learning
$175M25 Jan 2022 California, United States
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Surveyor Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: